Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is overvalued on EV/EBITDA.
Target Price
The average target price of PRME is 7.2 and suggests 97% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell